ADBiotech Co

ADBiotech Co LT Debt/Equity

The Long-Term Debt to Equity Ratio of ADBiotech Co (179530.KQ) as of Nov 22, 2026 is 0.20. In the previous year, Long-Term Debt to Equity Ratio was 0.88 — a change of -77.63% (lower).

LT Debt/Equity

0.20

YoY

-77.63%

Last updated:

Long-Term Debt to Equity Ratio of ADBiotech Co is 2025 0.20 . Long-Term Debt to Equity Ratio of ADBiotech Co was 2024 0.88 . It decreases by -77.63% lower compared to the previous year.

The ADBiotech Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
0.17 KRW
Jan 1, 2019
0.01 KRW
Jan 1, 2020
0.43 KRW
Jan 1, 2021
0.63 KRW
Jan 1, 2022
0.19 KRW
Jan 1, 2023
0.30 KRW
Jan 1, 2024
0.88 KRW
Jan 1, 2025
0.20 KRW
The ADBiotech Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.20-77.63%
0.88+197.28%
0.30+58.18%
0.19-70.29%
0.63+46.77%
0.43+4,334.44%
0.01-94.43%
0.17-22.28%
0.22-80.17%
1.13—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ADBiotech Co Stock analysis

What does ADBiotech Co do? ADbiotech Co., Ltd. generates revenue by manufacturing and selling chemical products across two distinct business segments. The Veterinary Medicine segment focuses on the production of antibiotics, anticoccidial agents, antimicrobial agents, nervous system agents, and synthetic antibacterial agents for use in pharmaceuticals and stockbreeding. This division serves customers in the animal health sector by providing essential medical compounds for livestock and other animals. The Supplementary Feed segment complements the core operations by manufacturing and selling functional supplementary feeds and other related products. This segment targets the stockbreeding and fisheries industries, offering nutritional solutions to enhance animal health and productivity. By combining these two segments, ADBiotech Co., Ltd. delivers a comprehensive range of chemical and feed-based solutions to its clients in Chuncheon, Gangwon-Do. ADBiotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ADBiotech Co stock

Long-Term Debt to Equity Ratio of ADBiotech Co is 0.20 in 2025.

Long-Term Debt to Equity Ratio of ADBiotech Co changed from 0.88 to 0.20, representing a -77.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio ADBiotech Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's ADBiotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ADBiotech Co

All Key Metrics — ADBiotech Co